The Angiopoietin-Like Protein 3 and 8 Complex Interacts with Lipoprotein Lipase and Induces LPL Cleavage.


Journal

ACS chemical biology
ISSN: 1554-8937
Titre abrégé: ACS Chem Biol
Pays: United States
ID NLM: 101282906

Informations de publication

Date de publication:
19 03 2021
Historique:
pubmed: 4 3 2021
medline: 14 7 2021
entrez: 3 3 2021
Statut: ppublish

Résumé

Lipoprotein lipase (LPL) is the key enzyme that hydrolyzes triglycerides from triglyceride-rich lipoproteins. Angiopoietin-like proteins (ANGPTL) 3, 4, and 8 are well-characterized protein inhibitors of LPL. ANGPTL8 forms a complex with ANGPTL3, and the complex is a potent endogenous inhibitor of LPL. However, the nature of the structural interaction between ANGPTL3/8 and LPL is unknown. To probe the conformational changes in LPL induced by ANGPTL3/8, we found that HDX-MS detected significantly altered deuteration in the lid region, ApoC2 binding site, and furin cleavage region of LPL in the presence of ANGPTL3/8. Supporting this HDX structural evidence, we found that ANGPTL3/8 inhibits LPL enzymatic activities and increases LPL cleavage. ANGPTL3/8-induced effects on LPL activity and LPL cleavage are much stronger than those of ANGPTL3 or ANGPTL8 alone. ANGPTL3/8-mediated LPL cleavage is blocked by both an ANGPTL3 antibody and a furin inhibitor. Knock-down of furin expression by siRNA significantly reduced ANGPT3/8-induced cleavage of LPL. Our data suggest ANGPTL3/8 promotes furin-mediated LPL cleavage.

Identifiants

pubmed: 33656326
doi: 10.1021/acschembio.0c00954
doi:

Substances chimiques

Angiopoietin-like Proteins 0
RNA, Small Interfering 0
Deuterium AR09D82C7G
Lipoprotein Lipase EC 3.1.1.34
Furin EC 3.4.21.75

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

457-462

Auteurs

Najia Jin (N)

Diabetes and Complications Therapeutic Area, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States.

William F Matter (WF)

Diabetes and Complications Therapeutic Area, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States.

Laura F Michael (LF)

Diabetes and Complications Therapeutic Area, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States.

Yuewei Qian (Y)

Laboratory for Experimental Medicine, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States.

Tarun Gheyi (T)

Lilly Biotechnology Center, Eli Lilly and Company, San Diego, California 92121, United States.

Leticia Cano (L)

Centro de Investigación Lilly S.A., 28108 Alcobendas, Spain.

Carlos Perez (C)

Centro de Investigación Lilly S.A., 28108 Alcobendas, Spain.

Celia Lafuente (C)

Centro de Investigación Lilly S.A., 28108 Alcobendas, Spain.

Howard B Broughton (HB)

Centro de Investigación Lilly S.A., 28108 Alcobendas, Spain.

Alfonso Espada (A)

Centro de Investigación Lilly S.A., 28108 Alcobendas, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH